13-15 September 2023 Abstract & early booking deadlines: 13 July 2023. This meeting will cover the broader PI3K pathway, including basic research in signalling and biology, the generation of improved pharmacological pathway modulators, and their use in cancer, immunity and rare diseases. A better understanding of the clinical observations using PI3K pathway inhibitors – alongside progress in the pharmacological targeting of these enzymes, such as mutant-selective inhibitors, effective AKT inhibitors, and PI3K activators – is heralding a new phase of research and clinical development. Basic science investigations also continue to provide new insight into the pathway and the clinical observations, opening new opportunities for drug re-positioning. Together, these developments have created renewed interest in the field, which we are aiming to capture with this meeting. Programme Coordinators:
Topics include:
Oral communication slots are available at this meeting. All attendees, particularly researchers in the early stages of their career, are invited to submit a poster abstract for consideration as an oral communication. You can submit your abstract here. This event is sponsored by:
Biochemical Society BursariesWe offer a wide variety of grants and bursaries to help you attend this event and save money on registration fees! Support is available to cover registration, accessibility, companion costs and more. Apply during the registration process for any of the following schemes:
Not a member of the Biochemical Society? Join today and save up to £100 on your registration fee. |